IMAJ | volume 27
Journal 7, July 2025
pages: 442-447
1 Department of Cardiology, Samson Assuta Ashdod University Hospital, Ashdod, Israel
2 Biochemistry Laboratory, Samson Assuta Ashdod University Hospital, Ashdod, Israel
3 Hematology Laboratory, Samson Assuta Ashdod University Hospital, Ashdod, Israel
4 Clinical Microbiology Laboratory, Samson Assuta Ashdod University Hospital, Ashdod, Israel
5 Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel
Summary
Background:
Inflammatory and thrombotic markers play crucial roles in risk stratification for various diseases.
Objectives:
To investigate the relative importance of inflammation, measured by C-reactive protein (CRP), and platelet turnover, indicated by immature platelet fraction (IPF), in predicting outcomes for patients with cardiovascular disease, coronavirus disease 2019 (COVID-19), and bacterial infections.
Methods:
In this retrospective observational study, we analyzed data from 1473 individuals admitted to the Samson Assuta Ashdod University Hospital between 2018 and 2022. Patients were categorized based on CRP and IPF levels, with a focus on 280 patients in the high CRP/low IPF or high IPF/low CRP tertiles.
Results:
The high CRP low IPF group demonstrated significantly higher mortality rates compared to the low CRP high IPF group (13.5% vs. 0.8%,
P < 0.001). Logistic regression analysis revealed that the high CRP and low IPF combination was the strongest predictor of mortality (odds ratio 12.951, 95% confidence interval 1.409–119.020,
P = 0.024).
Conclusions:
The combination of inflammatory (CRP) and thrombotic (IPF) markers provides superior prognostic information compared to individual disease diagnoses in patients with cardiovascular disease, COVID-19, and bacterial infections.